Hemodynamic effects of midodrine after spaceflight in astronauts without orthostatic hypotension

Aviation Space and Environmental Medicine

Volumn 77, Issue 4, 2006, Pages 429-433

  Platts, Steven H ^a   Ziegler, Michael G ^b   Waters, Wendy W ^c   Meck, Janice V ^d  

^a UNIVERSITIES SPACE RESEARCH ASSOCIATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WYLE LABORATORIES   (United States)

^d NASA JOHNSON SPACE CENTER   (United States)

Author keywords

1 adrenergic agonist; De glymidodrine; Microgravity; Orthostatic intolerance

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; MIDODRINE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BODY POSTURE; CONTROLLED STUDY; COSMONAUT; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PRESYNCOPE; RISK ASSESSMENT; SPACE; SPACE FLIGHT; TACHYCARDIA; TREATMENT OUTCOME;

ADRENERGIC ALPHA-AGONISTS; ASTRONAUTS; BLOOD PRESSURE; CARDIAC OUTPUT; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; MIDODRINE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPACE FLIGHT; SYNCOPE; TACHYCARDIA; TILT-TABLE TEST;

EID: 33645710474     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Abriel H, Schlapfer J, Keller DI, et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly 2004; 134:685-94.
2. Brignole M. Randomized clinical trials of neurally mediated syncope. J Cardiovasc Electrophysiol 2003; 14:364-9.
3. Chaimberg KH, Travis KW. Supine hypertension during general anesthesia in a patient taking midodrine. Anesth Analg 2002; 95:1196-7 (table).
4. Childs C, Goldring S, Tann W, et al. Suprasternal Doppler ultrasound for assessment of stroke distance. Arch Dis Child 1998; 79:251-5.
5. D'Aunno DS, Dougherty AH, deBlock HF, et al. Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts. Am J Cardiol 2003; 91:494-7.
6. Ehringer H. [Study of human peripheral hemodynamics after i.v. infusion of a small dosage of dl-1-(2′,5′-dimethoxyphenyl)-2- glycinamidoethanol-(1) hydrochloride (=st 1085)]. Int Z Klin Pharmakol Ther Toxikol 1971; 4:415-20.
7. Fritsch-Yelle JM, Whitson PA, Bondar RL, et al. Subnormal norepinephrine release relates to presyncope in astronauts after spaceflight. J Appl Physiol 1996; 81:2134-41.
8. Grobecker HF, Kees F. Pharmacokinetic parameters and haemodynamic actions of midodrine in young volunteers. Int Angiol 1993; 12:119-24.
9. Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988; 38:951-5.
10. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol 2002; 52:342-5.
11. Lin YF, Wang JY, Denq JC, et al. Midodrine improves chronic hypotension in hemodialysis patients. Am J Med Sci 2003; 325:256-61.
12. Martin DS, Meek JV. Presyncopal/non-presyncopal outcomes of post spaceflight stand tests are consistent from flight to flight. Aviat Space Environ Med 2004; 75:65-7.
13. McTavish D, Goa KL. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989; 38:757-77.
14. Meek JV, Reyes CJ, Perez SA, et al. Marked exacerbation of orthostatic intolerance after long- vs. short-duration spaceflight in veteran astronauts. Psychosom Med 2001; 63:865-73.
15. Meek JV, Waters WW, Ziegler MG, et al. Mechanisms of postspaceflight orthostatic hypotension: low alpha 1-adrenergic receptor responses before flight and central autonomic dysregulation postflight. Am J Physiol Heart Circ Physiol 2004; 286:H1486-95.
16. Piwinski SE, Jankovic J, McElligott MA. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol 1994; 34:466-71.
17. Platts SH, Ziegler MG, Waters WW, et al. Midodrine prescribed to improve recurrent post-spaceflight orthostatic hypotension. Aviat Space Environ Med 2004; 75:554-6.
18. Prakash S, Garg AX, Heidenheim AP, et al. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant 2004; 19:2553-8.
19. Ramsdell CD, Mullen TJ, Sundby GH, et al. Midodrine prevents orthostatic intolerance associated with simulated spaceflight. J Appl Physiol 2003; 90:2245-8.
20. Schrage WG, Eisenach JH, Dinenno FA, et al. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol 2004; 97:1978-84.
21. Vincent GM. Long QT syndrome. Cardiol Clin 2000; 18:309-25.
22. Waters WW, Ziegler MG, Meek JV. Post-spaceflight orthostatic hypotension occurs mostly in women and is predicted by low vascular resistance. J Appl Physiol 2002; 92:586-94.
23. Zachariah PK, Bloedow DC, Moyer TP, et al. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther 1986; 39:586-91.
24. Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep 2001; 1:216-27.